Tirzepatide shows MACE non-inferiority and slows eGFR decline in T2D, HFpEF patients
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology.
Abstract
Dual GIP/GLP-1 agonist tirzepatide achieved MACE non-inferiority vs. dulaglutide, slowed eGFR decline in T2D, and reduced heart failure events in obesity with HFpEF.